Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aimmune Therap

< Previous 1 2 3 4 5 6 7 Next >
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Two Upcoming Medical Meetings
Aimmune Therapeutics to present Phase 2 data on AR101, its investigational biologic therapy for treatment of peanut allergy, at the annual meetings of FAAM in Rome and ACAAI in San Francisco. 
From Business Wire News Releases
Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real
Aimmune completes and exceeds North American enrollment target ahead of schedule in Phase 3 PALISADE trial of AR101; Company accelerates plans for real-world experience study in the U.S. 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Y
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics Announces Second Quarter 2016 Financial Results
Aimmune Therapeutics reports financial results for the second quarter ended June 30, 2016. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
Aimmune Therapeutics will present a company overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016, in New York City at 9:10 a.m. ET. 
From Business Wire News Releases
Aimmune Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
Dr. Mary Rozenman, SVP, Corporate Development and Strategy at Aimmune Therapeutics will present a company overview at the Cantor Fitzgerald healthcare conference on July 12, 2016, in New York City. 
From Business Wire News Releases
Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer
Aimmune Therapeutics appointed Daniel Adelman, M.D., as Chief Medical Officer. Dr. Adelman has decades of industry experience and is a food allergy and immunology expert. 
From Business Wire News Releases
Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
Aimmune Therapeutics reports new Phase 2 extended maintenance data supports the safety & tolerability profile of AR101 for peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016
Aimmune Therapeutics announces late-breaker presentation on AR101 for treating peanut allergy at EAACI; company will host conference call on Monday, June 13, 2016, to discuss Phase 2 results. 
From Business Wire News Releases
Aimmune Therapeutics to Present at Upcoming June Investor Conferences
Aimmune Therapeutics will present at the upcoming Goldman Sachs and JMP Securities investor conferences in June. 
From Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics Presents Data on Biomarkers and Potential to Predict Response to Peanut Allergy Treatment With AR101
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics Appoints Douglas Sheehy as General Counsel and Secretary
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics Announces Phase 2 Follow-On Study of AR101 for the Treatment of Peanut Allergy Demonstrated Increased Desensitization and Improved Tolerability with Low-Dose Maintenance
Aimmune Therapeutics announced data from the open-label ARC002 Phase 2 trial of its lead product candidate, AR101 for the treatment of peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results; Company Began 2016 with Approximately $200 Million in Cash and Investments and Its Phase 3 PALISADE Trial Underway. 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
Aimmune Therapeutics will participate in the Cowan and Barclays Capital investor conferences in March. 
From Business Wire News Releases
Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016
Aimmune Therapeutics will announce its fourth quarter and full year 2015 financial results on Thursday, March 3, 2016, followed by a webcast and conference call. 
From Business Wire News Releases
Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Aimmune Therapeutics announces presentation at AAAAI 2016 and late-breaking abstract posted. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
Aimmune Therapeutics CEO Stephen Dilly, MBBS, PhD, to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 9:00 a.m. Eastern Time. 
From Business Wire News Releases
Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics enrolls first patient in Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy and provides year-end update and upcoming milestones review. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics CEO Dr. Stephen Dilly to Present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2015, at 11 a.m. Pacific Time 
From Business Wire News Releases
Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
Aimmune Therapeutics announced the appointment of Jeffrey H. Knapp as Chief Operating Officer. He will join the company on or about February 1, 2016. 
From Business Wire News Releases
How it All Plays Out - New Research on Aimmune Therapeutics, Straight Path Communications, SunRun and NTELOS
Tags Business & Professional Services
From ACCESSWIRE
Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
Aimmune will present at the Piper Jaffray 27th Annual Healthcare Investor Conference in New York City on Tuesday, December 1, 2015, at 2:00 p.m. Eastern Time. 
From Business Wire News Releases
Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy
Aimmune Therapeutics, Inc., announced positive findings for its ARC002 clinical trial, a follow-on Phase 2 study of the company’s lead product candidate, AR101 for the treatment of peanut allergy. 
From Business Wire News Releases
Covered Call Alerts For Tesla Motors, Ralph Lauren, Opko Health, BP and Aimmune Therapeutics Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for TSLA, RL, OPK, BP and AIMT. 
From PR Newswire
Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months... 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the 2015 Credit Suisse Healthcare... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X